AB Science SA

1,4500

25-апреля-25 11:29:36

15 мин. задержка

Акции

-0,0200

-1,36%

Сегодняшний диапазон

1,4220 - 1,4560

ISIN

FR0010557264

Источник

Cboe

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

23 апр 2025 12:59:03 Источник Nasdaq GlobeNewswire
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

14 апр 2025 12:02:30 Источник Nasdaq GlobeNewswire
AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

04 мар 2025 02:35:15 Источник Nasdaq GlobeNewswire
AB Science today provides an update on its masitinib platform

29 янв 2025 13:03:14 Источник Nasdaq GlobeNewswire
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

24 янв 2025 12:01:01 Источник Nasdaq GlobeNewswire
AB Science will participate in the Biomed Forum investors conference

22 янв 2025 12:59:47 Источник Nasdaq GlobeNewswire
AB Science provides a summary of the webcast held on December 16, 2024

17 дек 2024 13:04:08 Источник Nasdaq GlobeNewswire
AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

11 дек 2024 12:06:34 Источник Nasdaq GlobeNewswire
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

28 окт 2024 12:47:33 Источник Nasdaq GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

17 окт 2024 13:28:54 Источник Nasdaq GlobeNewswire
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

10 окт 2024 02:28:04 Источник Nasdaq GlobeNewswire
AB Science announces a slight delay in the publication of its 2024 half-year financial report

30 сен 2024 12:33:35 Источник Nasdaq GlobeNewswire
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

26 сен 2024 02:28:30 Источник Nasdaq GlobeNewswire
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

23 сен 2024 11:51:06 Источник Nasdaq GlobeNewswire
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

08 июл 2024 01:56:02 Источник Nasdaq GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

28 июн 2024 06:31:02 Источник Nasdaq GlobeNewswire
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

31 май 2024 10:30:34 Источник Nasdaq GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

29 май 2024 12:02:52 Источник Nasdaq GlobeNewswire
AB Science reports its revenues for the year 2023 and provides an update on its activities

15 май 2024 14:16:47 Источник Nasdaq GlobeNewswire
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036

13 май 2024 12:08:35 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.